Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoxia22.02.02.0030.001598%
Ichthyosis acquired23.01.02.0010.000145%Not Available
Ileus07.13.01.0010.000436%
Ileus paralytic07.02.05.0010.000218%Not Available
Immune system disorder10.02.01.0010.000363%Not Available
Impaired healing08.03.02.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.000145%Not Available
Increased appetite14.03.01.003; 08.01.09.0270.000465%Not Available
Increased insulin requirement05.06.01.006; 14.06.01.006--Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.0050.000145%Not Available
Infection11.01.08.002--Not Available
Infection susceptibility increased11.01.08.004; 10.02.01.046--Not Available
Injection site extravasation08.02.03.002; 12.07.03.0020.000320%Not Available
Injection site induration12.07.03.007; 08.02.03.0070.000145%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.003676%Not Available
Injection site vesicles23.03.01.024; 12.07.03.051; 08.02.03.0510.000494%Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Insulin resistance14.06.02.003; 05.06.02.0030.000581%Not Available
Intestinal infarction24.04.08.008; 07.15.02.0060.000145%Not Available
Intestinal perforation07.04.06.0020.000291%Not Available
Intracranial pressure increased17.07.02.0020.000828%Not Available
Intraocular pressure increased13.07.04.002--Not Available
Intraventricular haemorrhage24.07.04.008; 17.08.01.0170.000145%Not Available
Iridocyclitis06.04.03.0010.000756%Not Available
Iris adhesions06.06.06.0030.000392%Not Available
Iris atrophy06.06.06.0040.001598%Not Available
Iritis10.02.01.022; 06.04.03.0020.001947%Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice neonatal18.04.08.001; 09.01.01.008; 01.06.04.0060.000145%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene